NCT02431260

An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies

A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies

• Status: Terminated
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 69 (actual)
• Sponsor: Incyte Corporation · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This was a study of INCB054329 given to patients with advanced malignancies that were conducted in three treatment groups. Each treatment group had a dose escalation (Part 1) and a dose expansion (Part 3), two of the treatment groups also had an intra-patient dose titration (Part 2).

Conditions

• Solid Tumors and Hematologic Malignancy

Interventions

Type	Name	Description
DRUG	INCB054329 Monotherapy	Initial cohort dose of INCB054329 monotherapy at the protocol-specified starting dose in the treatment group A (TGA), with subsequent cohort escalations in the three treatment groups (TGA, TGB, and TGC) based on protocol-specific criteria

Timeline

• Start date: 2015-04-14
• Primary completion: 2018-01-31
• Completion: 2018-01-31
• First posted: 2015-04-30
• Last updated: 2019-06-14
• Results posted: 2019-06-14

Locations

12 sites across 1 country: United States